Open AccessNon‐Toxic Virucidal Macromolecules Show High Efficacy Against Influenza Virus Ex Vivo and In Vivo
Author(s) -
Kocabiyik Ozgun,
Cagno Valeria,
Silva Paulo Jacob,
Zhu Yong,
Sedano Laura,
Bhide Yoshita,
Mettier Joelle,
Medaglia Chiara,
Da Costa Bruno,
Constant Samuel,
Huang Song,
Kaiser Laurent,
Hinrichs Wouter L. J.,
Huckriede Anke,
Le Goffic Ronan,
Tapparel Caroline,
Stellacci Francesco
Publication year - 2021
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202001012
Subject(s) - in vivo , virology , ex vivo , influenza a virus , virus , pandemic , oseltamivir , infectivity , in vitro , viral envelope , biology , chemistry , microbiology and biotechnology , covid-19 , medicine , biochemistry , infectious disease (medical specialty) , disease , pathology
Influenza is one of the most widespread viral infections worldwide and represents a major public health problem. The risk that one of the next pandemics is caused by an influenza strain is high. It is important to develop broad‐spectrum influenza antivirals to be ready for any possible vaccine shortcomings. Anti‐influenza drugs are available but they are far from ideal. Arguably, an ideal antiviral should target conserved viral domains and be virucidal, that is, irreversibly inhibit viral infectivity. Here, a new class of broad‐spectrum anti‐influenza macromolecules is described that meets these criteria and display exceedingly low toxicity. These compounds are based on a cyclodextrin core modified on its primary face with long hydrophobic linkers terminated either in 6'sialyl‐ N ‐acetyllactosamine (6’SLN) or in 3’SLN. SLN enables nanomolar inhibition of the viruses while the hydrophobic linkers confer irreversibility to the inhibition. The combination of these two properties allows for efficacy in vitro against several human or avian influenza strains, as well as against a 2009 pandemic influenza strain ex vivo. Importantly, it is shown that, in mice, one of the compounds provides therapeutic efficacy when administered 24 h post‐infection allowing 90% survival as opposed to no survival for the placebo and oseltamivir.